Expanded Access to Provide BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
- Conditions
- Advanced Non-small Cell Lung CancerCancer
- Registration Number
- NCT06761976
- Lead Sponsor
- Bayer
- Brief Summary
The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie BAY2927088's activity in HER2-mutated non-small cell lung cancer?
How does BAY2927088 compare to standard-of-care therapies for HER2 exon 20-mutant NSCLC in clinical trials?
Which biomarkers predict response to BAY2927088 in HER2-mutated metastatic NSCLC patients?
What are the safety profiles and management strategies for BAY2927088 in HER2-driven lung cancer?
Are there combination therapies or competitor drugs targeting HER2 mutations in advanced NSCLC?